Navafenterol (AZD8871) in patients with mild asthma: a randomised placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of this novel inhaled long-acting dual-pharmacology bronchodilator

Abstract Background Navafenterol (AZD8871) is an inhaled long-acting dual-pharmacology muscarinic antagonist/β2-adrenoceptor agonist (MABA) in development for the treatment of obstructive airways diseases. The safety, tolerability, pharmacodynamics, and pharmacokinetics of navafenterol were investig...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Eulalia Jimenez, Carol Astbury, Muna Albayaty, Ulrika Wählby-Hamrén, Beatriz Seoane, Cristina Villarroel, Helena Pujol, Maria Jesus Bermejo, Ajay Aggarwal, Ioannis Psallidas
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2020-09-01
Edice:	Respiratory Research
Témata:	Bronchodilator Asthma MABA, dual-pharmacology muscarinic receptor antagonist β2-adrenoceptor agonist Safety Pharmacokinetics
On-line přístup:	http://link.springer.com/article/10.1186/s12931-020-01470-5
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!